Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

TherapeuticsMD, Inc. (29TA.SG)

Compare
0.7750
+0.0300
+(4.03%)
At close: April 11 at 9:30:41 PM GMT+2
Loading Chart for 29TA.SG
  • Previous Close 0.7450
  • Open 0.7350
  • Bid 0.8350 x --
  • Ask 0.8950 x --
  • Day's Range 0.7350 - 0.7750
  • 52 Week Range 0.6550 - 2.0200
  • Volume 0
  • Avg. Volume 11
  • Market Cap (intraday) 10.14M
  • Beta (5Y Monthly) 0.95
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1800
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

www.therapeuticsmd.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 29TA.SG

View More

Performance Overview: 29TA.SG

Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

29TA.SG
24.76%
S&P 500 (^GSPC)
8.81%

1-Year Return

29TA.SG
58.99%
S&P 500 (^GSPC)
3.16%

3-Year Return

29TA.SG
93.95%
S&P 500 (^GSPC)
21.55%

5-Year Return

29TA.SG
98.31%
S&P 500 (^GSPC)
92.25%

Compare To: 29TA.SG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 29TA.SG

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    10.14M

  • Enterprise Value

    12.02M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.71

  • Price/Book (mrq)

    0.37

  • Enterprise Value/Revenue

    7.68

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -123.85%

  • Return on Assets (ttm)

    -5.32%

  • Return on Equity (ttm)

    -8.16%

  • Revenue (ttm)

    1.76M

  • Net Income Avi to Common (ttm)

    -2.31M

  • Diluted EPS (ttm)

    -0.1800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.06M

  • Total Debt/Equity (mrq)

    26.21%

  • Levered Free Cash Flow (ttm)

    -2.99M

Research Analysis: 29TA.SG

View More

Company Insights: 29TA.SG

Research Reports: 29TA.SG

View More

People Also Watch